Just reported
From Edwards Lifesciences's results release of 2026년 11월 4일; its quarterly report has since been filed.
Actual
US$1.72B
+10% y/y
-1.5% q/q
Guided
US$1.67B
midpoint
Actual
US$0.53
+6.0% y/y
+26% q/q
Guided
—
No guide given
Actual
US$299.1M
-2.6% y/y
-42% q/q
Guided
—
No guide given
Q4 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →매출 비중은 nine months ended September 30, 2026 기준 추정치이며, 제출된 보고서의 수치가 아닙니다.
SAPIEN
A family of tissue valves delivered through a catheter to replace a diseased aortic valve; some systems are also used for pulmonary valve replacement.
PASCAL
A catheter-delivered device that helps bring together the leaflets of a leaking mitral or tricuspid valve.
EVOQUE
A tissue valve delivered through a catheter to replace a leaking tricuspid valve.
SAPIEN M3
A tissue valve delivered through a catheter to replace a diseased mitral valve.
INSPIRIS RESILIA, KONECT RESILIA, and MITRIS RESILIA
Surgical tissue valve products for aortic and mitral valve replacement; KONECT is a tissue valve conduit used in complex combined procedures.
Edwards makes devices that replace or repair damaged heart valves. Some are delivered through a catheter, a thin tube passed through a blood vessel, while others are implanted during open-heart surgery. Hospitals and heart specialists use these devices to treat diseases affecting the aortic, mitral, and tricuspid valves.
Edwards Lifesciences Corporation이(가) 미국 증권거래위원회(SEC)에 직접 제출한 공시로 만들었습니다. 수치는 보고된 그대로이며, 주당 이력은 오늘의 주식 수 기준으로 재계산했습니다. 이것은 사업을 설명하는 자료입니다. 투자 자문이 아니며 어떤 매수나 매도도 권유하지 않습니다.
The themes Edwards Lifesciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
US$105.83+1.7%11월 11일 종가
2026년 9월 30일까지의 수치 (2026년 11월 4일 제출 10-Q 기준)
Edwards Lifesciences sells catheter-delivered heart valves and repair devices, plus surgical replacement valves, to hospitals treating people with heart valve disease.
회사 전망: 2026 회계연도 4분기 매출 US$1.7B~US$1.8B — 전년 대비 8.9% 증가
Grade A+
주가 아래 띠는 각 날짜의 등급으로, 그 시점까지 공개된 자료만으로 산출했습니다.
Edwards Lifesciences Corporation의 등급 이력 41개 분기 중 2개를 표시하고 있습니다. 나머지 39개는 2016년 10월까지 거슬러 올라갑니다.